Some wonder why I read biotech industry journals. Well, because you find gold nuggets such as this. There is nothing conclusive, but its clear that risk of cancer from gene therapies was known otherwise there would be no need to IMPROVE assessment.

Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article

https://www.liebertpub.com/doi/10.1089/hum.2024.033

https://web.archive.org/web/20240829180234/https://www.liebertpub.com/doi/10.1089/hum.2024.033

#breakthestate #anarchy #covid #mrna #avv #crispr #genome

Reply to this note

Please Login to reply.

Discussion

I mostly agree with the sentiment here, but to be fair, talking about improvement the *assessment* itself is not an indication that they know the *risk* to be present. They want to determine if risk is present, but the assessment of risk is inadequate (for determining risk).

It's still fucked - the fact that they aren't sure of the risk assessment capacity but are still recommending these treatments is itself a little worrisome. But it's not exactly what you're saying.